Centene announced that it has successfully completed the previously announced divestiture of Magellan Rx to Prime Therapeutics LLC. Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNC:
- CENTENE COMPLETES DIVESTITURE OF MAGELLAN RX
- Managed care company returns will be tough to keep replicating, WSJ says
- CENTENE SIGNS DEFINITIVE AGREEMENT TO DIVEST MAGELLAN SPECIALTY HEALTH
- EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE
- CENTENE COMPLETES DIVESTITURE OF ITS SPANISH AND CENTRAL EUROPEAN BUSINESSES
